Regenerative Medical Technology Group Inc.
For the period ended Dec 31, 2025. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. PROPERTIES
| ITEM 2. | PROPERTIES |
|---|
We maintain our current principal office at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432. Our phone number is (800) 956-3935. This location serves as our administrative headquarters in the United States.
Our primary operational facilities are located in Cancún, Quintana Roo, Mexico, where we conduct patient treatments, physician training, and manufacturing of regenerative medicine products through our subsidiary, Global Stem Cells Group, Inc. (GSCG), and its division Cellgenic.
The Cancún operations are situated in the Tulum Trade Center, a modern commercial complex located at Boulevard Luis Donaldo Colosio, Manzana 1, Lote 3, Supermanzana 9, Cancún, Quintana Roo, Mexico. This facility serves as both our clinical center for regenerative therapies and our advanced manufacturing site for mesenchymal stem cells (MSCs), exosomes, peptide-based products, and related biologics.
Lease History and Current Arrangements:
| ◾ | Initial Lease: Global Stem Cell Group, Inc. entered into a lease agreement with HELLIMEX, S.A. DE CV beginning January 16, 2022, and originally ending on January 15, 2024. The leased space consisted of approximately 1,647 square feet, with a monthly rent of $2,714 and a security deposit of $5,588. In January 2022, we initiated the buildout of the clinic and procurement of equipment. The Cancún facility is accredited by both the Mexican General Health Council and COFEPRIS (Mexico’s federal health regulatory authority equivalent to the FDA), enabling compliant operations for stem cell therapies and manufacturing. |
| ◾ | Expansion Lease: Due to business growth and the need for additional space, we entered into a new lease with RIVIERA MAYA, S.A. DE C.V. beginning January 16, 2024, and originally ending on January 15, 2026. This added approximately 1,216 square feet to support expanded clinical and manufacturing activities. |
| ◾ | Lease Extension: On December 31, 2025, the Company signed a five-year extension to the combined lease arrangements, effective from December 31, 2025, through December 31, 2029. The monthly rent and security deposit terms remained unchanged at $2,714 per month and $5,588, respectively. This extension provides long-term stability for our core operations. |
Additional Leases in 2025:
| ◾ | On July 31, 2025, the Company signed a three-year lease for additional space consisting of 1,290 square feet located at Av. Bonampak #SM4A M1 Lote 4C, Int. Local 401, Col. SM 4A, Localidad Benito Juárez, Cancún, Quintana Roo C.P. 77500, MX. The lease commences on July 31, 2025, and ends on June 30, 2028, with a monthly rent of $10,000 for the first year and a 3.56% annual increase beginning in the second year. A security deposit of $20,000 was paid. |
| ◾ | On October 30, 2025, the Company signed a five-year lease for additional office space consisting of 1,205 square feet at the Tulum Trade Center. The lease commences on November 1, 2025, and ends on October 31, 2030, with a monthly rent of $3,500 for the first year and a 4% annual increase beginning in the second year. A security deposit of $5,300 was paid. |
The Cancún facility is fully licensed by COFEPRIS to function as a Stem Cell Collection Center, Stem Cell Bank, and advanced manufacturing center. It supports our vertical integration strategy, enabling in-house production of high-quality regenerative products for our global clinic network and distribution. The facility’s strategic location in Cancún facilitates access to international patients and aligns with our focus on medical tourism and regenerative treatments in Mexico.
We do not own any real property and lease all our facilities on market terms. We believe our current leased properties are adequate for our present and near-term needs, with flexibility to expand as our operations grow in key international markets. We continue to evaluate additional locations for future clinic expansions and potential manufacturing sites, subject to regulatory and market conditions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.